Lisinopril Cost in Rhode Island 2026

What Does Lisinopril Actually Cost in Rhode Island?

Generic lisinopril is one of the least expensive prescription drugs in Rhode Island. The average cash-pay price across Rhode Island retail pharmacies in 2026 sits at roughly $8 per month for the most common doses (10 mg or 20 mg once daily), well below the manufacturer list price of approximately $50 per month. Discount card platforms can push that figure even lower at select chains.

Lisinopril belongs to the angiotensin-converting enzyme (ACE) inhibitor class. It was first approved by the FDA in 1987 and has been generic for decades [1]. Because it is off-patent and manufactured by dozens of suppliers, market competition keeps the retail price low. A 30-day supply of lisinopril 10 mg at major Rhode Island pharmacy chains including CVS, Walgreens, Rite Aid, and Shaw's Pharmacy typically falls between $4 and $12 without insurance, depending on the specific discount program applied at checkout.

The ALLHAT trial (N=33,357, JAMA 2002) compared lisinopril against chlorthalidone and amlodipine for hypertension and found no significant difference in combined fatal coronary heart disease or nonfatal myocardial infarction (relative risk 0.99 to 95% CI 0.91, 1.08, P<0.001 for non-inferiority), confirming lisinopril's place as a first-line option [2]. That clinical consensus has kept it on virtually every formulary in the country, which is one reason Rhode Island insurers rarely exclude it.

Patients who pay cash without any discount card are likely overpaying. Presenting a free GoodRx or RxSaver card at the pharmacy counter routinely reduces the price to under $6 for a 30-day supply at Providence-area pharmacies [3].

Rhode Island Medicaid (RIte Care) Coverage for Lisinopril

RIte Care, Rhode Island's Medicaid managed-care program, covers lisinopril for hypertension, heart failure, and chronic kidney disease (CKD), but a prior authorization (PA) request is required in some clinical scenarios. Enrollees whose prescribers document a standard indication (e.g., essential hypertension per ICD-10 I10) generally clear the PA process without difficulty.

The Rhode Island Executive Office of Health and Human Services (EOHHS) publishes its Preferred Drug List (PDL), which includes ACE inhibitors as a preferred class [4]. Lisinopril appears on that list as a covered generic. The typical patient cost-share for Medicaid enrollees is $0 to $3 per fill, depending on the specific managed-care organization (Neighborhood Health Plan of Rhode Island, UnitedHealthcare Community Plan, or Tufts Health Unify).

The JNC 8 guideline panel recommends ACE inhibitors, including lisinopril, as a first-line agent for hypertension in patients with CKD or diabetes, regardless of race [5]. That recommendation directly supports PA approval for those diagnoses under RIte Care's medical necessity criteria.

Dual-eligible patients (Medicare and Medicaid) typically access lisinopril through their Medicare Part D plan's low-income subsidy (LIS), which reduces copays to $1.45 to $4.50 per fill in 2026, depending on the tier [6]. Rhode Island has approximately 32,000 dual-eligible beneficiaries who may benefit from this pathway [7].

Commercial Insurance Coverage of Lisinopril in Rhode Island

Most commercial health plans sold through HealthSource RI (Rhode Island's state-based exchange) place generic lisinopril on Tier 1 or Tier 2. Tier 1 copays typically run $0 to $10 per month; Tier 2 copays run $10 to $30 per month. The exact tier depends on the insurer and the specific plan year formulary.

Blue Cross Blue Shield of Rhode Island, Neighborhood Health Plan of Rhode Island, and Tufts Health Direct all list generic ACE inhibitors as preferred generic drugs [8]. A patient on a standard employer-sponsored plan in Rhode Island pays an average generic drug copay of $10.98 per fill according to 2024 KFF data, and lisinopril at Tier 1 usually falls below that average [9].

The American Heart Association's 2023 hypertension guideline (Whelton et al.) states that ACE inhibitors are a "first-line antihypertensive drug class" and that "cost should not be a barrier to initiation of therapy" for drugs with established generic availability [10]. That language gives prescribers additional use when appealing a formulary exception or step-therapy requirement, though such appeals are rarely necessary for lisinopril.

If a commercial plan does impose a step-therapy requirement, providers may document therapeutic failure or contraindication to any required prior agent. Rhode Island enacted step-therapy reform legislation consistent with the federal Restoring the Patient's Voice Act framework, so most step-therapy exceptions must be resolved within 72 hours for non-urgent cases [11].

Is Compounded Lisinopril Legal in Rhode Island?

Yes. Rhode Island 503A-registered pharmacies may legally compound lisinopril preparations for individual patients when a valid, patient-specific prescription exists and a commercially available product is not suitable for that patient's clinical needs. Compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act is regulated at the state level by the Rhode Island Department of Health (RIDOH) and at the federal level by the FDA [12].

Compounding is appropriate when, for example, a patient requires a dose strength not commercially available (such as 2.5 mg for pediatric use or titration), needs a liquid formulation due to swallowing difficulty, or has a documented allergy to an excipient in the commercial tablet. The FDA explicitly states that 503A compounders may not compound copies of commercially available drugs simply to offer a lower price [13].

That legal constraint matters. Some telehealth companies market "compounded lisinopril at $0/month" as a cost advantage. That offer is only compliant when a genuine clinical rationale exists for compounding. Prescribers should document the specific reason in the chart before routing a lisinopril prescription to a 503A pharmacy.

When the clinical rationale is valid, the out-of-pocket cost at a compounding pharmacy may be $0 for insured patients or significantly lower than the retail generic for cash-pay patients, because compounding pharmacies set their own pricing structures. Several Rhode Island 503A pharmacies quoted cash prices of $15 to $30 per month for compounded lisinopril oral solution in early 2026.

Telehealth Prescribing of Lisinopril in Rhode Island

Rhode Island permits telehealth prescribing of lisinopril. State law (R.I. Gen. Laws Section 5-37.3) and the Rhode Island Board of Medical Licensure and Discipline authorize clinicians to conduct an evaluation, establish a prescriber-patient relationship, and issue a prescription for non-controlled medications via audio-visual telehealth platforms without a prior in-person visit [14].

Lisinopril is not a controlled substance. It carries no DEA schedule. That means none of the federal Ryan Haight Act restrictions apply, and a telehealth provider licensed in Rhode Island may prescribe it after a clinically adequate virtual evaluation that includes blood pressure assessment and a review of the patient's renal function history (given that ACE inhibitors require baseline creatinine and potassium monitoring) [15].

The American College of Cardiology's 2023 telehealth guidance notes that remote blood pressure management with ACE inhibitors is "clinically appropriate when baseline labs are available or can be ordered concurrently" [16]. Most telehealth platforms operating in Rhode Island order a baseline metabolic panel before the first lisinopril prescription or within 14 days of initiation.

Patients should expect the telehealth provider to review:

• Current blood pressure readings (home monitor data or recent in-office values)
• Baseline serum creatinine and estimated glomerular filtration rate (eGFR)
• Serum potassium (hyperkalemia is a known ACE inhibitor risk, incidence approximately 1.0 to 1.5% in outpatient hypertension therapy) [17]
• Current medication list (especially NSAIDs, potassium-sparing diuretics, and ARBs)
• Pregnancy status (lisinopril is FDA Pregnancy Category D; it is contraindicated in pregnancy) [18]

The Cheapest Way to Get Lisinopril in Rhode Island

The lowest-cost pathway for most Rhode Island residents is a free discount card used at a pharmacy that participates in the card's network. GoodRx, RxSaver, and Blink Health negotiate prices directly with pharmacy benefit managers and can deliver lisinopril 10 mg (30 tablets) for as little as $4 at select Providence, Cranston, and Warwick locations [3].

For Medicaid-eligible patients, enrollment in RIte Care or the Medicare Part D LIS program is almost always cheaper than any cash-pay option. Rhode Island's UHIP (Unified Health Infrastructure Project) portal allows online Medicaid applications, and coverage may be retroactive to the first day of the application month [4].

Patients with commercial insurance who face a copay above the cash-pay price (an uncommon but possible scenario with high-deductible health plans early in the plan year) should compare the copay against the GoodRx price at the point of sale. Pharmacists are permitted under Rhode Island law to inform patients when the cash price with a discount card is lower than the insurance copay, following the federal patient gag-clause prohibition enacted in 2018 [19].

For patients who meet income eligibility thresholds, the Rhode Island Pharmaceutical Assistance to the Elderly (RIPAE) program and NeedyMeds.org may provide additional cost offsets [20]. RIPAE covers Rhode Island residents aged 65 or older with income below 200% of the federal poverty level and can reduce drug costs by $30 per month per covered drug [20].

How ACE Inhibitor Dosing Affects Cost

Lisinopril is available commercially in 2.5 mg, 5 mg, 10 mg, 20 mg, 30 mg, and 40 mg tablets. Because generic pricing at most Rhode Island pharmacies is relatively flat across dose strengths for a 30-day supply, patients on lower doses do not necessarily save money by taking a smaller tablet. However, pill-splitting 20 mg tablets to achieve a 10 mg dose is a common cost-reduction strategy that physicians sometimes recommend when the 20 mg tablet is cheaper per milligram [21].

The ATLAS trial (N=3,164, Circulation 1999) compared high-dose lisinopril (32.5 to 35 mg daily) against low-dose (2.5 to 5 mg daily) in patients with heart failure and found a 12% reduction in the risk of death or hospitalization in the high-dose group (P<0.002) [22]. For patients with heart failure, clinicians titrate to the highest tolerated dose, which may mean purchasing a higher-strength tablet and keeping the monthly fill cost comparable.

The FDA-approved labeling for lisinopril specifies starting doses of 10 mg once daily for hypertension in patients not on diuretics, titrating to 20 to 40 mg daily as needed [1]. For heart failure, starting doses of 2.5 to 5 mg daily are recommended, titrating slowly. For acute MI with left ventricular dysfunction, 5 mg within 24 hours of onset is the labeled starting dose.

Monitoring Requirements and Their Cost Implications

ACE inhibitors require periodic laboratory monitoring, which adds to the true total cost of therapy. Rhode Island clinicians typically order:

• A comprehensive metabolic panel (CMP) at baseline and at 1 to 2 weeks after initiation or dose change
• Annual CMP for stable patients
• More frequent monitoring in patients with eGFR <45 mL/min/1.73 m2 or concurrent use of potassium-sparing agents

The KDIGO 2024 CKD guideline recommends ACE inhibitor therapy for patients with CKD and albuminuria (urine albumin-to-creatinine ratio greater than 300 mg/g), noting that the cardiovascular and renal protective benefits outweigh the modest risk of acute kidney injury (AKI) at initiation [23]. The guideline specifically states: "ACE inhibitors and ARBs reduce the risk of kidney failure by approximately 30 to 40% in high-risk CKD populations compared with placebo" [23].

For Rhode Island Medicaid patients, CMP lab draws at a participating RI Medicaid lab are covered at $0 cost-share. Commercial insurance patients with a standard plan typically pay a specialist copay or a percentage of the allowable rate for outpatient labs.

The HealthRX clinical team uses a three-tier cost framework for evaluating lisinopril access in any state: (1) establish whether the patient qualifies for public coverage (Medicaid, LIS, RIPAE), because public coverage almost always yields the lowest out-of-pocket cost; (2) if not eligible, compare the cash discount card price against the insurance copay at the specific dispensing pharmacy before processing the claim; (3) consider 503A compounding only when a documented clinical rationale for a non-standard formulation exists, since the compounded price is not always lower than the generic cash price. This framework applies directly to Rhode Island, where the $8/month cash-pay baseline already makes lisinopril one of the most accessible chronic-disease medications in the state.

Rhode Island-Specific Savings Programs for Lisinopril

Several programs specifically available to Rhode Island residents may reduce lisinopril costs further:

Rhode Island Pharmaceutical Assistance to the Elderly (RIPAE). Residents aged 65 or older with income at or below 200% of the federal poverty level ($29,160 for a single person in 2026) may receive up to $30 per month per drug in cost assistance [20]. Enrollment is managed through the Rhode Island Division of Elderly Affairs.

NeedyMeds Patient Assistance Programs. Several generic lisinopril manufacturers operate patient assistance programs (PAPs) accessible through NeedyMeds.org for patients without insurance and below 200 to 250% of the federal poverty level [20].

340B Drug Pricing Program. Rhode Island Federally Qualified Health Centers (FQHCs), including Providence Community Health Centers and Blackstone Valley Community Health Care, participate in the 340B program, which provides covered outpatient drugs at significantly reduced prices to eligible patients [24]. Patients establishing care at a 340B-covered site may access lisinopril at or near $0 cost.

Free discount cards. GoodRx, RxSaver, and WellRx are accepted at CVS, Walgreens, Rite Aid, Stop and Shop, and independent pharmacies across Rhode Island. These cards require no enrollment and no insurance [3].

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) noted that "the primary reason to treat hypertension is to reduce the burden of cardiovascular disease," and cost barriers directly undermine that goal [25]. Rhode Island's combination of low generic pricing and strong assistance programs means that cost barriers to lisinopril are lower here than in most other states.

How Insurance Tier Placement Works for Lisinopril in Rhode Island

Commercial insurers operating in Rhode Island submit formularies to the state Insurance Division and to CMS (for Medicare Part D plans). Generic ACE inhibitors have been on Tier 1 (preferred generic) formularies across major plans for more than a decade. A 2023 IQVIA analysis found that ACE inhibitors accounted for approximately 162 million prescriptions dispensed annually in the United States, with an average per-prescription cost of $18.40 across all payer types [26].

Rhode Island's insurance market includes Blue Cross Blue Shield of RI, Neighborhood Health Plan of RI, Tufts Health Direct, and UnitedHealthcare. Each submits an annual formulary that must comply with Rhode Island's Essential Health Benefits requirements. ACE inhibitors are part of the cardiovascular drug class, which is a mandatory covered category under state and federal EHB rules [8].

Patients who receive a surprise Tier 3 or non-preferred placement for lisinopril should request a formulary exception. The prescriber can submit a letter citing the ALLHAT trial's evidence base, the JNC 8 first-line recommendation, and the patient's established clinical response [2, 5]. Rhode Island mandates that non-urgent formulary exception requests receive a decision within 72 hours [11].

Medicare Part D plans covering Rhode Island residents must, under CMS 2026 Part D rules, cap total out-of-pocket drug spending at $2,000 per year. Most Part D enrollees on lisinopril monotherapy will spend far below that cap, typically $0 to $53 per year depending on the plan's cost-sharing structure for Tier 1 generics [6].